<DOC>
	<DOC>NCT02166437</DOC>
	<brief_summary>In this study, the investigators would like to analyze the bone mineral density (BMD) , bone turnover makers, and fracture prevention effects of bisphosphonate and denosumab randomly divided following daily teriparatide in Japanese patients under clinical practice. The participants are treated in the investigators hospital, who are under severe osteoporotic condition.</brief_summary>
	<brief_title>Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese</brief_title>
	<detailed_description>Registry criteria: Patients treated in the investigators hospital using teriparatide. Enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low BMD (&lt; young adult mean 65%). Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds participants</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>severe osteoporotic patients cancer, hypercalcemia, etc (i.e. patients who could not use bisphosphonate, denosmab, teriparatide)</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>BMD</keyword>
	<keyword>teriparatide</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>denosmab</keyword>
</DOC>